Advanced search

Vol 55, No 2 (2024)
Review article
Published online: 2024-01-31

open access

View PDF Download PDF file
Supp./Additional Files
Page views 222
Article views/downloads 171
Get Citation

Connect on Social Media

Connect on Social Media

Asciminib a new player in treatment of TKI-resistant/intolerant chronic phase chronic myelogenous leukemia

Krzysztof Lewandowski1
DOI: 10.5603/ahp.98474
Acta Haematol Pol 2024;55(2):62-72.

Abstract

The introduction in 1998 of imatinib mesylate (IM), a first-generation BCR-ABL1 tyrosine kinase inhibitor (1G-TKI), to the treatment of chronic myelogenous leukemia patients in the chronic phase (CML-CP), significantly improved the prognosis of a previously incurable disease with a prognosed 5-year-long overall survival and progression-free survival of 91.7% and 94.7%, respectively. Long term follow-up studies of CML-CP patients verified the initial results, showing a 10-year overall response rate of 82–83.2%. In about one quarter of CML-CP patients, IM primary/secondary resistance or intolerance is diagnosed. After switching to a two generation BCR-ABL1 TKI (dasatinib, nilotinib, bosutinib), a complete cytogenetic response is obtained in only c. 50% of CML-CP patients. Also the frequency of deep molecular responses (DMR: MR4.0 and MR4.5) is relatively low. The results of 2G-TKI treatment are particularly unsatisfactory in patients carrying the TKI resistant BCR::ABL1 kinase domain mutants (BCR::ABL1 KD), especially BCR-ABL1 T315I. For this reason, other orally biocompatible compounds have been developed to target BCR-ABL T315I. One of these is ponatinib, which allows a major molecular response (MMR) and MR4.5 to be obtained in 40% and 24% of severely TKIs-pretreated CML-CP patients, respectively. The latter represent a new class of allosteric BCR-ABL1 tyrosine kinase inhibitor [asciminib (ABL001)], specifically targeting the ABL myristoyl pocket of BCR-ABL tyrosine kinase. Its application in CML-CP patients previously treated with at least two TKIs resulted in an MMR rate and a MR4.5 rate of 37.6% and 10.8%, respectively, at 96 weeks. The favorable asciminib response and tolerance profile was also confirmed in real life conditions, even in subjects with previous ponatinib therapy failure (MR4.5 in 10.5%). Recent data suggests that asciminib may be used in the first line or in combination with a 1G- or 2G-TKI. This latter strategy may enhance the rate of DMR obtained and increase the number of patients eligible for an attempt at treatment-free remission.

Keywords: chronic myelogenous leukemiatyrosine kinase inhibitorscytogenetic responsemolecular responseBCR::ABL1 KD mutationsasciminib

Article available in PDF format

View PDF Download PDF file

References

  1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2(5): 561–566.
    CrossRefPubMed
  2. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996; 56(1): 100–104.
    PubMed
  3. O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11): 994–1004.
    CrossRefPubMed
  4. Druker BJ, Guilhot F, O'Brien SG, et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23): 2408–2417.
    CrossRefPubMed
  5. Deininger M, O'Brien S, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009; 114(22): 1126.
    CrossRef
  6. Hochhaus A, Larson RA, Guilhot F, et al. IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10): 917–927.
    CrossRefPubMed
  7. Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017; 31(11): 2398–2406.
    CrossRefPubMed
  8. Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017; 31(3): 593–601.
    CrossRefPubMed
  9. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22(6): 1200–1206.
    CrossRefPubMed
  10. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117(4): 1141–1145.
    CrossRefPubMed
  11. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011; 118(17): 4567–4576.
    CrossRefPubMed
  12. Scalzulli E, Caocci G, Efficace F, et al. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. Ann Hematol. 2021; 100(5): 1213–1219.
    CrossRefPubMed
  13. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(2): 440–453.
    CrossRefPubMed
  14. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20): 2333–2340.
    CrossRefPubMed
  15. Brümmendorf TH, Cortes JE, Milojkovic D, et al. BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022; 36(7): 1825–1833.
    CrossRefPubMed
  16. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(2): 440–453.
    CrossRefPubMed
  17. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014; 32(5): 415–423.
    CrossRefPubMed
  18. Sokal JE. Evaluation of survival data for chronic myelocytic leukemia. Am J Hematol. 1976; 1(4): 493–500.
    CrossRefPubMed
  19. Copland M. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. Br J Haematol. 2022; 199(5): 665–678.
    CrossRefPubMed
  20. Mukherjee S, Kalaycio M. Accelerated phase CML: outcomes in newly diagnosed vs. progression from chronic phase. Curr Hematol Malig Rep. 2016; 11(2): 86–93.
    CrossRefPubMed
  21. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
    CrossRefPubMed
  22. Hochhaus A, Breccia M, Saglio G, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020; 34(6): 1495–1502.
    CrossRefPubMed
  23. Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023; 37(11): 2150–2167.
    CrossRefPubMed
  24. Lauseker M, Hehlmann R, Hochhaus A, et al. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023; 37(11): 2231–2236.
    CrossRefPubMed
  25. Senapati J, Sasaki K, Issa GC, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023; 13(1): 58.
    CrossRefPubMed
  26. Russo Rossi A, Breccia M, Abruzzese E, et al. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 2013; 98(3): 399–403.
    CrossRefPubMed
  27. Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021; 14(1): 44.
    CrossRefPubMed
  28. Ochi Y, Yoshida K, Huang YJ, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021; 12(1): 2833.
    CrossRefPubMed
  29. Soverini S, Mancini M, Bavaro L, et al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018; 17(1): 49.
    CrossRefPubMed
  30. de Lavallade H, Finetti P, Carbuccia N, et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res. 2010; 34(2): 254–257.
    CrossRefPubMed
  31. Villuendas R, Steegmann JL, Pollán M, et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 2006; 20(6): 1047–1054.
    CrossRefPubMed
  32. Alves R, Gonçalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021; 13(19): 4820.
    CrossRefPubMed
  33. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014; 26(3): 428–442.
    CrossRefPubMed
  34. Soverini S, Bavaro L, De Benedittis C, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020; 135(8): 534–541.
    CrossRefPubMed
  35. Schmitt MW, Pritchard JR, Leighow SM, et al. Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias. Clin Cancer Res. 2018; 24(21): 5321–5334.
    CrossRefPubMed
  36. Chandran RK, Geetha N, Sakthivel KM, et al. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. Gene. 2019; 686: 85–91.
    CrossRefPubMed
  37. Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018; 132(9): 948–961.
    CrossRefPubMed
  38. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30(5): 1044–1054.
    CrossRefPubMed
  39. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018; 132(4): 393–404.
    CrossRefPubMed
  40. Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016; 48: 84–91.
    CrossRefPubMed
  41. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021; 138(21): 2042–2050.
    CrossRefPubMed
  42. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023; 98(4): 658–665.
    CrossRefPubMed
  43. Breccia M, Abruzzese E, Castagnetti F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018; 97(9): 1577–1580.
    CrossRefPubMed
  44. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017; 543(7647): 733–737.
    CrossRefPubMed
  45. Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018; 61(18): 8120–8135.
    CrossRefPubMed
  46. Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. Blood Res. 2023; 58(S1): S29–S36.
    CrossRefPubMed
  47. Shanmuganathan N, Hughes TP. Asciminib for chronic myeloid leukaemia: Next questions. Br J Haematol. 2022; 199(3): 322–331.
    CrossRefPubMed
  48. Rea D, Mauro M, Hochhaus A, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. Journal of Clinical Oncology. 2022; 40(16_suppl): 7004.
    CrossRef
  49. Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020; 98: 106458.
    CrossRefPubMed
  50. Cowan-Jacob SW, Fendrich G, Floersheimer A, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr. 2007; 63(Pt 1): 80–93.
    CrossRefPubMed
  51. Qiang W, Antelope O, Zabriskie MS, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017; 31(12): 2844–2847.
    CrossRefPubMed
  52. Cortes J, Hughes T, Mauro M, et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial. Blood. 2020; 136(Supplement 1): 47–50.
    CrossRef
  53. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019; 381(24): 2315–2326.
    CrossRefPubMed
  54. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021; 138(21): 2031–2041.
    CrossRefPubMed
  55. Hughes TP, Goh YT, Ottmann O, et al. Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with cml-chronic phase with failure of prior TKI therapy. Blood. 2016; 128(22): 625–625.
    CrossRef
  56. Sasaki K, Mauro M, Levy M, et al. ASC2ESCALATE: a phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI). Blood. 2022; 140(Supplement 1): 6784–6786.
    CrossRef
  57. Cortes JE, Hughes T, Geissler J, et al. Efficacy and safety results from ASC4MORE, a randomized study of asciminib (ASC) add-on to imatinib (IMA), continued IMA, or switch to nilotinib (NIL) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) not achieving deep molecular responses (DMRs) with ≥1 year of IMA. Blood. 2022; 140(Supplement 1): 195–197.
    CrossRef
  58. Luna A, Pérez-Lamas L, Boque C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022; 101(10): 2263–2270.
    CrossRefPubMed
  59. Pérez-Lamas L, Luna A, Boque C, et al. Toxicity of asciminib in real clinical practice: analysis of side effects and cross-intolerance with tyrosine kinase inhibitors. Blood. 2022; 140(Supplement 1): 3925–3928.
    CrossRefPubMed
  60. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021; 138(21): 2042–2050.
    CrossRefPubMed
  61. Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022; 139(24): 3474–3479.
    CrossRefPubMed
  62. Cortes JE, Hochhaus A, Takahashi N, et al. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022; 18(38): 4161–4170.
    CrossRefPubMed
  63. Chiwata M, Itonaga H, Sato S, et al. Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: a report from The Nagasaki CML Study Group. Intern Med. 2021; 60(14): 2207–2216.
    CrossRefPubMed
  64. Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010; 4: 315–323.
    CrossRefPubMed
  65. Adattini JA, Gross AS, Wong Doo N, et al. Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience. Pharmacol Res Perspect. 2022; 10(5): e01005.
    CrossRefPubMed
  66. Huguet F, Cayuela JM, Cambier N, et al. AdheRMC Investigators. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Br J Haematol. 2019; 187(5): 615–626.
    CrossRefPubMed
  67. Nekoukar Z, Moghimi M, Salehifar E. A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. Blood Res. 2021; 56(4): 229–242.
    CrossRefPubMed
  68. Latagliata R, Stagno F, Annunziata M, et al. Frontline dasatinib treatment in a "real-life" cohort of patients older than 65 years with chronic myeloid leukemia. Neoplasia. 2016; 18(9): 536–540.
    CrossRefPubMed
  69. Latagliata R, Attolico I, Trawinska MM, et al. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. Hematol Oncol. 2021; 39(3): 401–408.
    CrossRefPubMed
  70. Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020; 4(3): 530–538.
    CrossRefPubMed
  71. Mauro MJ, Hughes TP, Kim DW, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023; 37(5): 1048–1059.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Acta Haematologica Polonica

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice